Evidence map›Paper›PMID 23438733›Full record

ArticleMolecular & cellular proteomics : MCP2013

A classifier based on accurate mass measurements to aid large scale, unbiased glycoproteomics.

John W Froehlich, Eric D Dodds, Mathias Wilhelm, Oliver Serang, Judith A Steen, Richard S Lee

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Glycomic and glycoproteomic analysis of glycoproteins-a tutorial.Analytical and bioanalytical chemistry · 2017
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

John W FroehlichDepartment of Urology and Urological Diseases Research Center, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Eric D Dodds
Mathias Wilhelm
Oliver Serang
Judith A Steen
Richard S Lee
Boston Children's Hospital · USHarvard University · USUniversity of Nebraska–Lincoln · US

Funding

Supplement request for Training GrantT32NS007473 · NINDS · CHILDREN'S HOSPITAL BOSTON · PI Elizabeth C. Engle, Thomas L. Schwarz · 1999 to 2026
$6.9M
Regulation of SMN and Identification of its Downstream TargetR01NS066973 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI STEEN, JUDITH A · 2010 to 2014
$2.2M
Early Validation of Urinary Biomarkers of Renal ObstructionR01DK096238 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI LEE, RICHARD SANG-YONG · 2013 to 2017
$1.3M
The effect of congenital renal obstruction on the urinary proteome in infantsK08DK077836 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI LEE, RICHARD SANG-YONG · 2007 to 2011
$755k
NIDDK NIH HHS DK077836NIDDK NIH HHS DK077836S1NIDDK NIH HHS K08 DK077836NIDDK NIH HHS R01 DK096238NINDS NIH HHS NS007473NINDS NIH HHS R01 NS066973NINDS NIH HHS R01NS066973NINDS NIH HHS T32 NS007473
6 · The paper itself

Abstract

Determining which glycan moieties occupy specific N-glycosylation sites is a highly challenging analytical task. Arguably, the most common approach involves LC-MS and LC-MS/MS analysis of glycopeptides generated by proteases with high cleavage site specificity; however, the depth achieved by this approach is modest. Nonglycosylated peptides are a major challenge to glycoproteomics, as they are preferentially selected for data-dependent MS/MS due to higher ionization efficiencies and higher stoichiometric levels in moderately complex samples. With the goal of improving glycopeptide coverage, a mass defect classifier was developed that discriminates between peptides and glycopeptides in complex mixtures based on accurate mass measurements of precursor peaks. By using the classifier, glycopeptides that were not fragmented in an initial data-dependent acquisition run may be targeted in a subsequent analysis without any prior knowledge of the glycan or protein species present in the mixture. Additionally, from probable glycopeptides that were poorly fragmented, tandem mass spectra may be reacquired using optimal glycopeptide settings. We demonstrate high sensitivity (0.892) and specificity (0.947) based on an in silico dataset spanning >100,000 tryptic entries. Comparable results were obtained using chymotryptic species. Further validation using published data and a fractionated tryptic digest of human urinary proteins was performed, yielding a sensitivity of 0.90 and a specificity of 0.93. Lists of glycopeptides may be generated from an initial proteomics experiment, and we show they may be efficiently targeted using the classifier. Considering the growing availability of high accuracy mass analyzers, this approach represents a simple and broadly applicable means of increasing the depth of MS/MS-based glycoproteomic analyses.

Indexed as

Protein Processing, Post-TranslationalAlgorithmsAnimalsCarbohydrate ConformationCarbohydrate SequenceComputer SimulationGlycoproteinsGlycosylationHumansMolecular Sequence AnnotationMolecular Sequence DataMolecular WeightPeptide FragmentsPolysaccharidesProteolysisProteomicsGlycoproteinsPeptide FragmentsPolysaccharides

Identifiers

PMID23438733
PMCPMC3617326
OpenAlexW2098004793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.